Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezharmia Tablet Post-marketing Surveillance in Relapsed or Refractory Peripheral T-cell Lymphoma
jRCT2031240338Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of valemetostat in peripheral T-cell lymphoma (PTCL), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Cumulative incidence of adverse events (safety specifications). Started Jun 2024; status: recruiting.
02
Drugs
valemetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on jRCT2031240338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240338.